Other languages Citius Pharmaceuticals, Inc.

Equities

CTXR

US17322U2078

Market Closed - Nasdaq Other stock markets 01:30:00 29/06/2024 am IST			5-day change	1st Jan Change
0.5837 ^USD	-8.54%		-4.15%	-22.84%

21/05	Citius Pharmaceuticals, Inc. Achieves Primary and Secondary Endpoints in Phase 3 Trial of Mino-Lok Antibiotic Lock Solution	CI
14/05	Citius Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	CI

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Citius Pharmaceuticals, Inc. Achieves Primary and Secondary Endpoints in Phase 3 Trial of Mino-Lok Antibiotic Lock Solution	21/05
Citius Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	15/05
Citius Pharmaceuticals Launches $15 Million Offering	26/04
Citius Pharmaceuticals, Inc. Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma	11/04
Citius Pharmaceuticals, Inc. Announces FDA Acceptance of the BLA Resubmission of LYMPHIR (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma	19/03
Citius Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	15/02
Sector Update: Health Care Stocks Gain Late Afternoon	15/02
Citius Pharmaceuticals Resubmits Application for Lymphoma Treatment	15/02
Citius Pharmaceuticals, Inc. Announces the Resubmission of the Biologics License Application to the U.S. Food and Drug Administration for Lymphir	14/02
Citius Pharmaceuticals Completes Enrollment in Phase 3 Trial for Mino-Lok	03/01
Citius Pharmaceuticals, Inc. Completes Enrollment in Pivotal Phase 3 Trial of its Mino-Lok Therapeutic to Salvage Catheters	02/01
Citius Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended September 30, 2023	30/12
Citius Pharmaceuticals, Inc. Announces Publication in Frontiers of Immunology of Positive Results from Solid Tumor Study of LYMPHIR? in Combination with Checkpoint Inhibitor	31/23/31
Sector Update: Health Care Stocks Advance in Late Afternoon Trading	25/23/25
Sector Update: Health Care Stocks Mixed in Afternoon Trading	24/23/24
Citius Pharmaceuticals to Merge Oncology Unit with TenX Keane Acquisition; Citius Shares Rise	24/23/24
Citius Pharmaceuticals, Inc. Announces Changes to its Audit Committee	26/23/26
Sector Update: Health Care Stocks Slipping Late Friday8 Afternoon	09/23/09
Sector Update: Health Care	09/23/09
Citius Pharmaceuticals Says No Additional Trials Required to Support Biologics License Application for Lymphir	08/23/08

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Citius Pharmaceuticals, Inc.

Equities

CTXR

US17322U2078

Other languages

Filters